Table 3.

Individual patient characteristics, toxicity, and outcomes

Patient #	Sex	Age	Ever smoker	Pk years	Histology	Pre-operative bevacizumab exclusion	Clinical stage	# Cisplatin	# Docetaxel	Pathologic stage	Pathologic downstage
2	F	47	Y	47	SQCLC	SQCLC	IIB	4	4	IA	Yes
6	M	64	Y	42	SQCLCa	SQCLC	IB	4	4	IB	No
7	M	50	Y	32	SQCLC	SQCLC	IB	4	2	IIB	No
8	F	65	Y	50	SQCLC	SQCLC	IIIA	4	4	IIIA	No
10	F	62	Y	18	SQCLC	SQCLC	IIB	4	4	IIA	Yes
11	M	67	Y	20	SQCLC	SQCLC	IIB	4	4	IIB	No
17	M	53	Y	40	SQCLC	SQCLC	IIIA	4	4	IIA	Yes
3	M	62	Y	74	ADC	Central	IIIA	4	4	IA	Yes
4	F	64	Y	20	ADC	Hemoptysis + central	IIIA	2	4	IIB	Yes
12	F	61	Y	31	ADC	Hemoptysis	IIIA	4	4	IB	Yes
14	M	49	Y	15	ADC	Central	IIIA	4	4	IB	Yes
16	M	59	N	–	ADC	Hemoptysis	IIIA	3	4	IIIA	No
18	F	51	Y	20	ADC	Central	IIIA	4	4	IIIA	No

Patient #	% viable tumor	Resection	PORT	# Bevacizumab	Reason bevacizumab stopped	Any bleeding toxicity	Grade 3+ toxicity	Grade 3+ toxicity attribution	Time to relapse or recurrence (mo)	Time to death (mo)	Follow-up (months)
2	60	1	N	18	Completed						69.4
6	40	0	N	14	Pt request						71.1
7	90	0	N	6	Recurrence	Grade 1			6.9	23.3	23.3
8	30	0	N	9	Toxicity (HTN)		HTN (grade 3)	Definite			63.3
10	95	1	Y	9	Pt request	Grade 1	Pleural effusion (grade 3)	Possible	44.8		49.6
							Lymphopenia (grade 3)	Possible
11	80	0	N	2	Toxicity (CVA—unrelated)		CVA (grade 4)	Unrelated	5.7	15.8	15.8
17	100	0	Y	12	Toxicity (MI/death)	Grade 1	PNA (grade 4)	Unrelated		14.0	14.0
							MI (grade 5)	Possible
3	0	0	N	17	Completed	Grade 1	HTN (grade 3)	Definite			64.2
4	30	0	N	8	Recurrence		Syncope (grade 3)	Possible	7.6	15.6	15.6
12	70	1	Y	9	Pt request						35.0
14	80	0	N	3	Pt request		DVT (grade 3)	Probable	9.8		32.5
16	40	0	Y	10	Toxicity (G1 epistaxis)	Grade 1	Lymphopenia (grade 3)	Possible	12.4		29.6
18	80	0	Y	5	Pt request		Lymphopenia (grade 3)	Possible	23.1		24.7

^aPt #6 had SQCLC histology at the time of diagnosis, but predominantly ADC histology at the time of tumor resection